kotak-logo
Valiant Laboratories Ltd's revenue decreased 64.8% YoY
  • 21 May 2025
  • Valiant Laboratories Ltd reported a 10.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 64.8%.
  • Its expenses for the quarter were up by 1.3% QoQ and down 56.4% YoY.
  • The net profit decreased 152.8% QoQ and decreased 112.4% YoY.
  • The earnings per share (EPS) of Valiant Laboratories Ltd declined at 0.3 during Q4FY25.

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Valiant Laboratories Ltd is a company whose specific products or services are not detailed in the provided data. As such, an in-depth understanding of the company's primary business operations, industry positioning, and recent developments remains unavailable. It is recommended to refer to external sources for additional information on the company's business activities, market presence, and strategic initiatives.

In Q4FY25, Valiant Laboratories Ltd reported a total income of ₹33.09 crores. This reflects a quarter-over-quarter (QoQ) decrease of 10.1% compared to Q3FY25, where the total income was ₹36.81 crores. Additionally, there is a notable year-over-year (YoY) decline of 64.8% from Q4FY24, which reported a total income of ₹94.01 crores. These figures highlight a downward trend in revenue generation over the specified periods.

The financial data for Valiant Laboratories Ltd indicates a negative trend in profitability for Q4FY25. The company reported a loss before tax of ₹-2.57 crores, contrasting with a profit before tax of ₹1.62 crores in Q3FY25, and a significant decline from the profit of ₹12.20 crores in Q4FY24. This represents a QoQ decrease of 258.6% and a YoY decrease of 121.1%. The profit after tax for Q4FY25 stood at ₹-1.24 crores, down from ₹2.35 crores in Q3FY25 and ₹10.00 crores in Q4FY24, marking declines of 152.8% QoQ and 112.4% YoY. The earnings per share for the quarter were ₹-0.30, compared to ₹0.50 in Q3FY25 and ₹2.40 in Q4FY24, showing decreases of 160.0% QoQ and 112.5% YoY.

Valiant Laboratories Ltd's total expenses for Q4FY25 amounted to ₹35.66 crores. This figure represents a slight increase of 1.3% QoQ from ₹35.19 crores in Q3FY25, but a significant reduction of 56.4% YoY from ₹81.81 crores in Q4FY24. The tax expense for the quarter was ₹-1.33 crores, which increased by 82.2% QoQ from ₹-0.73 crores in Q3FY25, while it decreased by 160.5% YoY from ₹2.20 crores in Q4FY24. These financial figures provide insight into the company's cost structure and tax liabilities over the specified periods.

Valiant Laboratories Ltd announced its Q1 FY 2025-26 results on 14 August, 2025.

Valiant Laboratories Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.

Key highlights of Valiant Laboratories Ltd Q1 FY 2025-26 results include:

  • Revenue: ₹47.48 crore
  • Net Profit: ₹1.82 crore
  • EBITDA: ₹3.05 crore
  • Year-over-Year Growth: 118.8%
  • Quarter-over-Quarter Growth: 43.5%

Valiant Laboratories Ltd reported a net loss of ₹1.82 crore in Q1 FY 2025-26, reflecting a -456.9% year-over-year growth.

Valiant Laboratories Ltd posted a revenue of ₹47.48 crore in Q1 FY 2025-26.